Gilead Sciences Inc 's Capital Expenditures in the fiscal year 2024 $ 523.00 millions
Gilead Sciences Inc 's Capital Expenditures in the fiscal year 2023 $ 585.00 millions
Gilead Sciences Inc 's Capital Expenditures in the fiscal year 2022 $ 728.00 millions
Gilead Sciences Inc 's Capital Expenditures in the fiscal year 2021 $ 579.00 millions
Gilead Sciences Inc 's Capital Expenditures in the fiscal year 2020 $ 650.00 millions
GILD Capital Expenditures third quarter 2025 Y/Y Growth Comment
Gilead Sciences Inc achieved in the third quarter 2025, above Company average Capital Expenditures improvement of 4.26% year on year, to $ 147.00 millions.
Looking into third quarter 2025 results within Biotechnology & Pharmaceuticals industry 18 other companies have achieved higher Capital Expenditures growth. While Gilead Sciences Inc ' s Capital Expenditures increase of 4.26% ranks overall at the positon no. 1222 in the third quarter 2025.
GILD Capital Expenditures ( Y/Y Growth %)
2025
2024
2023
2022
4th Quarter
December
-
-31.63 %
18.78 %
16.03 %
3rd Quarter
September
4.26 %
15.57 %
-22.29 %
12.95 %
2nd Quarter
June
-17.69 %
-6.47 %
-2.8 %
20.17 %
1st Quarter
March
-0.95 %
-3.67 %
-55.87 %
49.7 %
FY
-
-10.6 %
-19.64 %
25.73 %
Financial Statements
Gilead Sciences Inc 's third quarter 2025 Capital Expenditures
Capital Expenditures by Quarter for the Fiscal Years 2022, 2023, 2024, 2025
Gilead Sciences Inc 's Q/Q Capital Expenditures Growth
Capital Expenditures Q/Q Growth Statistics
High
Average
Low
305.31 %
16.95 %
-100 %
(Dec. 31, 2012)
GILD's III. Quarter Q/Q Capital Expenditures Comment
Gilead Sciences Inc achieved in the III. Quarter 2025 above company average sequential Capital Expenditures jump of 37.38%, to $ 147.00 millions, from $107.00 millions in the second quarter. GILD is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Biotechnology & Pharmaceuticals industry 27 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Gilead Sciences Inc 's Capital Expenditures growth quarter on quarter, overall rank is 727.
GILD's III. Quarter Q/Q Capital Expenditures Comment
Gilead Sciences Inc achieved in the III. Quarter 2025 above company average sequential Capital Expenditures jump of 37.38%, to $ 147.00 millions, from $107.00 millions in the second quarter. GILD is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Biotechnology & Pharmaceuticals industry 27 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Gilead Sciences Inc 's Capital Expenditures growth quarter on quarter, overall rank is 727.
Gilead Sciences Inc 's 12 Months Capital Expenditures Growth Year on Year
Capital Expenditures TTM Growth
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
12 Months Ending (Mar 31 2025)
12 Months Ending (Dec 31 2024)
12 Months Ending (Sep 30 2024)
Cumulative Capital Expenditures 12 Months Ending
$ 505.00
$ 499.00
$ 522.00
$ 523.00
$ 591.00
Y / Y Capital Expenditures Growth (TTM)
-14.55 %
-12.76 %
-10.15 %
-10.6 %
7.26 %
Year on Year Capital Expenditures Growth Overall
Ranking
# 1126
# 996
# 1324
# 1756
# 1625
Seqeuential Capital Expenditures Change (TTM)
1.2 %
-4.41 %
-0.19 %
-11.51 %
3.32 %
Seq. Capital Expenditures Growth (TTM) Overall
Ranking
# 1222
# 1036
# 1304
# 759
# 1280
Cumulative Capital Expenditures growth Comment
Gilead Sciences Inc 's cumulative 12 months Capital Expenditures continue to fall, but on the faster rate at -14.55% year on year, at Sep 30 2025 compare to the -12.76% decrease at Jun 30 2025. If the Gilead Sciences Inc 's fiscal year would end at Sep 30 2025, annual Capital Expenditures would be $505 millions.
In the Healthcare sector 133 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 996 to 1126.
Capital Expenditures TTM Y/Y Growth Company Ranking
Capital Expenditures TTM Q/Q Growth Company Ranking
Within:
No.
Industry
# 19
Sector
# 146
S&P 500
# 1222
Cumulative Capital Expenditures growth
Comment
Gilead Sciences Inc 's cumulative 12 months Capital Expenditures continue to fall, but on the faster rate at -14.55% year on year, at Sep 30 2025 compare to the -12.76% decrease at Jun 30 2025. If the Gilead Sciences Inc 's fiscal year would end at Sep 30 2025, annual Capital Expenditures would be $505 millions.
In the Healthcare sector 133 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 996 to 1126.
Capital Expenditures TTM Y/Y Growth Company Ranking
About Gilead Sciences Inc Capital Expenditures Growth Rates (GILD), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
7.30%